Nephros (NEPH) EBITDA (2010 - 2026)

Nephros' EBITDA history runs 17 years deep, the most recent figure standing at $97000.0 for Q1 2026.

• In Q1 2026, EBITDA fell 82.86% year-over-year to $97000.0; the TTM figure through Mar 2026 stood at $677000.0 (down 12.31% YoY), while the FY2025 annual figure was $1.1 million, up 19000.0% from the prior year.
• EBITDA was $97000.0 for Q1 2026 at Nephros, up from $18000.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $566000.0 in Q1 2025 to a low of -$3.2 million in Q3 2022.
• Historically, EBITDA has averaged -$432470.6 across 5 years, with a median of -$182000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 262.8% in 2022, then surged 434.91% in 2025.
• A 5-year view of EBITDA shows it stood at -$653000.0 in 2022, then retreated by 0.15% to -$654000.0 in 2023, then jumped by 148.47% to $317000.0 in 2024, then tumbled by 94.32% to $18000.0 in 2025, then jumped by 438.89% to $97000.0 in 2026.
• The last three EBITDA figures came in at $97000.0 (Q1 2026), $18000.0 (Q4 2025), and $314000.0 (Q3 2025), per Business Quant data.